D-project

ASCO 2022 | Ascentage Pharma Releases Updated Data Demonstrating Lisaftoclax's (APG-2575) Therapeutic Potential in Patients with R/R CLL/SLL

Retrieved on: 
Wednesday, June 8, 2022
FTD, MD Anderson Cancer Center, CDE, D-project, Biotechnology, RPD, Safety, Minor Use Animal Drug Program, CML, Breast cancer, Treatment, Cancer, Unity Biotechnology, Large-cell lung carcinoma, Center, ODD, Therapy, Multimedia, Infection, Priority review, NMPA, FDA, Stock exchange, Patient, Odds, AstraZeneca, Degenerative disease, Dana–Farber Cancer Institute, Motherboard, Hepatitis, BTD, Merck, Center for Drug Evaluation and Research, TKI, NSCLC, Mayo Clinic, IAP, Apoptosis, FAK, National Medical Products Administration, Mesothelioma, Pharmaceutical industry, Fine chemical, Pfizer, EU

Ascentage Pharma (6855.HK) is a globally focused biopharmaceutical company engaged in developing novel therapies for cancers, chronic hepatitis B, and age-related diseases.

Key Points: 
  • Ascentage Pharma (6855.HK) is a globally focused biopharmaceutical company engaged in developing novel therapies for cancers, chronic hepatitis B, and age-related diseases.
  • On October 28, 2019, Ascentage Pharma was listed on the Main Board of the Stock Exchange of Hong Kong Limited with the stock code 6855.HK.
  • Ascentage Pharma focuses on developing therapeutics that inhibit protein-protein interactions to restore apoptosis, or programmed cell death.
  • Ascentage Pharma is also the only company in the world with active clinical programs targeting all three known classes of key apoptosis regulators.

Ascentage Pharma Announces First Patient Dosed in China in the Pivotal Phase II Study of Lisaftoclax (APG-2575) in R/R CLL/SLL

Retrieved on: 
Tuesday, March 15, 2022
MSD, BTD, ODD, National Medical Products Administration, Western world, D-project, NMPA, CHB, BTK, Lymphoid neoplasms with plasmablastic differentiation, New Drug Application, TKI, NDA, IAP, Treatment, CML, Center for Drug Evaluation and Research, Apoptosis, Multimedia, AstraZeneca, Population, Death, CLL, Priority review, Biotechnology, FTD, Patient, CDE, Therapy, Motherboard, California Department of Alcohol and Drug Programs, ORR, Mayo Clinic, Degenerative disease, Leukemia, Cancer, HIV disease progression rates, Dana–Farber Cancer Institute, Lymphatic system, Phase II, MD Anderson Cancer Center, Center, Safety, Ageing, Hepatitis, SEER, Incidence, Infection, Stock exchange, Unity Biotechnology, Pharmaceutical industry, Fine chemical, EU, Pfizer

APG2575CC201 is a single-arm, open-label Phase II pivotal study designed to assess the efficacy and safety of lisaftoclax in patients with R/R CLL/SLL, with the overall response rate (ORR) as the primary endpoint.

Key Points: 
  • APG2575CC201 is a single-arm, open-label Phase II pivotal study designed to assess the efficacy and safety of lisaftoclax in patients with R/R CLL/SLL, with the overall response rate (ORR) as the primary endpoint.
  • CLL/SLL is a hematologic malignancy caused by mature B-cell neoplasms and is among the most common lymphoid neoplasms in the Western world.
  • Lisaftoclax is the first China-developed Bcl-2 inhibitor entering clinical development in China, and the second entering pivotal studies globally.
  • The company is conducting more than 40 Phase I/II clinical trials in the US, Australia, Europe, and China.

ASH 2021 | Ascentage Pharma to Present Three Studies of Olverembatinib (HQP1351), a Novel Drug Candidate for the Treatment of Drug-Resistant Leukemia, in Abstracts Including One Oral Report at ASH Annual Meeting

Retrieved on: 
Friday, November 5, 2021
MSD, NDA, Population, Progression-free survival, Biotechnology, Degenerative disease, IAP, Treatment, Dana–Farber Cancer Institute, Cancer, Efficacy, QOD, Therapy, Mayo Clinic, Diagnosis, TKI, BCR, Stock exchange, PFS, Mahr, PK, Leukopenia, Motherboard, Hepatitis, California Department of Alcohol and Drug Programs, Thrombocytopenia, Male, Patient, Center for Drug Evaluation and Research, D-project, Center, FTD, MMR, Mutation, Multimedia, Trae tha Truth, Anemia, CML, Apoptosis, AstraZeneca, OS, ODD, Priority review, Infection, MD Anderson Cancer Center, BCR-ABL, CDE, 2021 Essex County Council election, Unity Biotechnology, BTD, CHR, Pharmaceutical industry, Medical imaging, Health insurance, Fine chemical

Olverembatinib was orally administered once every other day (QOD)in 28-day cycles and at 11 dose cohorts ranging from 1 to 60 mg.

Key Points: 
  • Olverembatinib was orally administered once every other day (QOD)in 28-day cycles and at 11 dose cohorts ranging from 1 to 60 mg.
  • - From October 26, 2016, through February 2, 2021 (data cut-off date), 101 patients with CML-CP (n=86) or CML-AP (n=15) were enrolled and treated with olverembatinib.
  • In all, 84 (83.2%) patients received 2 prior lines of TKI-therapies, and 63 (62.4%) harbored the T315I mutation.
  • Ascentage Pharma (6855.HK) is a globally focused biopharmaceutical company engaged in developing novel therapies for cancers, chronic hepatitis B, and age-related diseases.